Interim report January – September 2023 for CombiGene AB (publ)

July – September 2023
• Net sales: TSEK 992 (5,213).
• Other operating revenues: TSEK 173 (8,285).
• Profit from financial items: TSEK -8,403 (3,953).
• Earnings per share: SEK -0.42 (0.20).

January – September 2023
• Net sales: TSEK 4,948 (21,354).
• Other operating revenues: TSEK 588 (20,888).
• Profit from financial items: TSEK -29,305 (5,785).
• Earnings per share: SEK -1.48 (0.29).
• Cash and cash equivalents: TSEK 107,187 (144,940).

Events during the period
• The Epilepsy Project progresses through optimization activities in preparation for in-human studies. (September 5)
• CombiGene chooses CDMO partner for the COZY01 pain project. (September 15)

Events after the end of the period
• Spark Therapeutics terminates collaboration agreement for the epilepsy project CG01 with CombiGene. (October 14)
• CombiGene and Zyneyro choose initial indication in the COZY01 pain project (October 26)
• CombiGene chooses Charles River as preclinical toxicology partner for the COZY01 pain project. (October 31)

Contacts

---

CombiGene AB (publ)
Peter Ekolind, CEO
Phone: [phone]
[e-mail]

www.combigene.com
CombiGene AB (publ) Agavägen 52A, SE-181 55 Lidingö, Sweden
[phone] [e-mail]

About CombiGene

---

CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.

Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.
 
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB.

Please read Ingeneious, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Ingeneious and press releases are available at www.combigene.com

Attachments

---

CombiGene Q3 2023 EN

© Modular Finance, source Nordic Press Releases